Natera Reports Strong Preliminary Q4 & Full‑Year 2025 Financial Results Fueled by Record Signatera Growth

Natera, Inc. (NASDAQ: NTRA), a global leader in cell‑free DNA and precision medicine, announced strong preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025, significantly driven by robust demand for its Signatera™ test. The company expects total revenues of about $660 million for Q4 2025, up ~39% from ~$476 million in Q4 2024, with revenues exceeding $600 million when excluding revenue true‑ups. For the full year, revenues are projected to reach ~$2.3 billion, a ~35% increase versus 2024, topping Natera’s previous outlook by roughly $40 million.  Test volumes also climbed sharply: ~923,600 tests in Q4 2025 (a 17% year‑over‑year increase) and ~3.53 million for the full year (up ~15%). Oncology testing surged, with ~233,300 oncology tests in Q4 2025 — a 55% increase over Q4 2024 — and clinical molecular residual disease (MRD) tests achieving record sequential quarterly growth. Cash inflows were approximately $30 million in Q4 2025 and over $100 million for the full year. Natera will present these results and additional business updates at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, and plans to release complete audited financials during its February earnings call. #Natera #Signatera #PrecisionMedicine #HealthcareFinance #SlimScan #GrowthStocks #CANSLIM